Laatste nieuws in biotech
Dutch Firm VitalFluid Raises Millions to Replace Chemical Pesticides with Electrified Water
Eindhoven, Sunday 25 October 2026
Dutch scale-up VitalFluid has secured €17.2 million to expand internationally, using just water, air, and electricity to protect commercial crops without leaving harmful chemical residues.
AstraZeneca's New Cancer Regimen Cuts Bladder Cancer Death Risk by 42 Per Cent
Brussels, Sunday 25 October 2026
AstraZeneca’s novel drug combination cut the risk of death by 42% in advanced bladder cancer patients, potentially establishing a breakthrough standard of care for those ineligible for standard chemotherapy.
Pfizer Advances Next-Generation Childhood Pneumonia Vaccine Following Strong Trial Results
Puurs, Sunday 25 October 2026
Pfizer’s experimental childhood pneumonia vaccine generated a 15-fold higher immune response against a deadly bacterial strain, potentially expanding protection to 84% of cases and reinforcing its core franchise.
Johnson & Johnson's Daily Pill Shows Exceptional Promise Against Advanced Prostate Cancer
Beerse, Saturday 24 October 2026
In early clinical trials, Johnson & Johnson’s experimental once-daily pill shrank or eliminated tumours in 69% of advanced prostate cancer patients, signalling a vital breakthrough in targeted therapy.
How Combining High-Tech and Biotech Could Revolutionise Dutch Innovation
Amsterdam, Sunday 18 October 2026
Invest-NL reveals that pairing Dutch semiconductor and precision engineering expertise with biotechnology can solve critical biomanufacturing scaling bottlenecks, creating a globally unique industrial ecosystem.
Brain implant startup secures new capital to restore human vision
Amsterdam, Saturday 17 October 2026
Dutch medtech firm Phosphoenix raised €1.3 million to prepare first-in-human clinical trials for its AI brain implant, which bypasses damaged eyes using 1,000 microelectrodes to directly stimulate sight.
Belgian biotech argenx advances promising coeliac disease drug to final testing phase
Ghent, Thursday 8 October 2026
Belgian biotech argenx has reported positive Phase 2 results for its coeliac disease drug candidate, FB102, which successfully prevented gluten-induced intestinal damage and will now advance to Phase 3 trials.
European Venture Capitalist Opens €100,000 Funding Call for Green Agriculture Startups
Amsterdam, Saturday 3 October 2026
Rockstart AgriFood has launched a €100,000 investment call for early-stage agritech startups, targeting key environmental solutions like carbon capture and regenerative agriculture.